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This paper addresses the calls for greater research on the antecedents of technological 
acquisitions by exploring a mechanism that drives both acquisition decision and target 
selection. Drawing from the RBV, this paper presents patent expiration as a driver behind 
pharmaceutical firms’ acquisition decisions and target selection. This paper argues that 
patent expiration constitutes a disruption to pharmaceutical firms’ pipelines and a threat to 
revenue and profit streams and that acquisitions represent a possible short- term solution for 
firms to replenish their patent portfolios and to ensure a continuous flow of revenues. Using 
a sample of US pharmaceutical firms, this paper shows that pharmaceutical firms engage 
in acquisitions when they face large amounts of patent expiration and when they are unable 
to internally replenish their patent portfolios. The results also show that acquiring firms 
have a preference for targets with resources similar to their existing portfolio of patents, 
which is explained by firms’ desire to minimize post- integration problems and possible 
disruptions derived from the difficulties in assimilation and commercial exploitation of 
distant knowledge. This is in contrast with previous studies indicating that acquiring firms 
benefit from knowledge bases that are more distant.
1.  Introduction
Mergers and acquisitions (M&As) are a highly popular strategy not only to access resources 
and capabilities but also as an important means of 
corporate development that permits firms’ growth 
(e.g., expansion of customers’ base and product di-
versification) and internationalization (Chakrabarti 
et al., 1994; Cartwright and Schoenberg, 2006; 
Ahuja and Novelli, 2014). In high- tech industries, 
M&As are an important way by which firms can ac-
cess technological assets and know- how held by the 
acquisition target (Capron, et al., 1998; Arora et al., 
2001; Graebner, 2004; Cassiman et al., 2005; Dao 
and Strobl, 2019), in particular when targets’ re-
sources and capabilities cannot be obtained through 
the factors market (Capron et al., 1998; Villalonga 
and McGahan, 2005; Capron and Mitchell, 2009).
Prior studies have provided important insights 
into the antecedents of acquisition behavior and 
post- M&A performance (Barkema and Schijven, 
2008; Haleblian et al., 2009; Rogan and Sorenson, 
2014; Meyer- Doyle et al., 2019; Arroyabe et al., 
2020; Welch et al., 2020). Yet, Yu et al. (2016) 
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and Welch et al. (2020) indicate there is still little 
understanding of the antecedents of M&As and call 
for greater research on the areas of M&A initiation 
(acquisition timing and decision) and target selec-
tion. In particular, they indicate that prior research 
has mainly focused on exogenous factors (e.g., 
industry and financial market factors) as primary 
explanations for the timing of acquisitions, which 
while explaining the overall acquisition activity of 
an industry do not explain why individual firms 
might be more or less likely to engage in acquisi-
tions at a particular point in time (Iyer and Miller, 
2008; Shi et al., 2012; Welch et al., 2020). Similarly, 
when it comes to target selection, previous studies 
have provided an analysis of the trade- off between 
complementarity and similarity, providing mixed 
evidence of the benefits of each, but they have not 
indicated when a particular acquirer will prefer one 
over the other (Yu et al., 2016). These are important 
questions as understanding the motives underlying 
acquisitions decisions enables to explain acquisi-
tions’ outcomes and facilitates providing adequate 
recommendations and strategies aimed at acquisi-
tions’ success (Schweizer, 2005; Shi et al., 2012; 
Welch et al., 2020). Addressing this gap, this paper 
presents a mechanism that explains the timing of 
the acquisition decision and target selection in 
the context of the pharmaceutical industry, where 
acquisitions and industry consolidation have been 
predominant.
Drawing from the resource- based view (RBV), 
this paper explores the role of patent expiration as a 
driver behind pharmaceutical firms’ acquisition deci-
sions and target selection. RBV understands acqui-
sitions as a means for bringing bundles of resources 
into firms and suggests that competitive advantage 
is derived from firms’ resources and capabilities. 
Within this RBV context, this paper considers pat-
ents as key resources of firms and argue that patent 
expiration constitutes a disruption to pharmaceutical 
firms’ pipelines and a threat to revenue and profit 
streams, where acquisitions represent a possible 
short- term solution for firms to replenish their patent 
portfolios and ensure a continuous flow of revenues 
(Ahuja and Katila, 2001; Ranft and Lord, 2002; Yu 
et al., 2016). The paper aligns with the RBV theory 
that suggests that competitive advantage originates 
from the resources (e.g., patents) and capabilities of 
the firm (Barney, 1991) and that acquisitions facili-
tate the exchange of firm- specific resources that oth-
erwise cannot be redeployed (Capron and Hulland, 
1999).
Using a sample of US pharmaceutical firms in the 
period 1985– 2010, the empirical results show that 
pharmaceutical firms engage in acquisitions when they 
face large amounts of patent expiration and when they 
are not able to internally replenish their patent port-
folios. Moreover, the results show that in these cases, 
pharmaceutical firms select targets with resources 
similar to their existing portfolio of patents; this is in 
contrast with previous studies indicating that acquir-
ing firms benefit from knowledge bases that are more 
distant (Shelton, 1988; Larsson and Finkelstein, 1999; 
Kim and Finkelstein, 2009; Makri et al., 2010; Sears, 
2017). The findings have important practical implica-
tions for managers, suggesting a proactive long- term 
innovation strategy and portfolio management.
This study makes two primary contributions to 
the literature on technological acquisitions. First, it 
broadens the explanation of motivation in techno-
logical acquisitions by incorporating patent expira-
tion as a driver. Second, it contributes to sparse and 
inconclusive literature on target choice by showing 
that the choice of knowledge base- relatedness is con-
tingent upon patent expiration.
2.  Theory and hypotheses
2.1.  The impact of patent expiration on 
pharmaceutical firms’ acquisitions 
decision
Since Barney’s (1991) pivotal work, the RBV of 
the firm has received widespread support in the 
strategy literature (Capron and Hulland, 1999). At 
the center of the RBV is the idea that resources and 
capabilities are heterogeneously distributed across 
firms and imperfect mobile, granting firms with the 
possibility of obtaining a competitive advantage 
(Barney, 1991; Peteraf, 1993). Firms’ resources 
are collections of knowledge and other tangi-
ble and intangible factors that firms possess that 
provide firms with the basis for obtaining a sus-
tainable competitive advantage. Patents are legal 
rights that protect the knowledge generated and 
exclude others from the use of proprietary inven-
tions (Henderson and Cockburn, 1994; Markman 
et al., 2004). RBV theory highlights the protection 
that patents provide against product rivals through 
greater control over distinctive product offerings 
(Hsu and Ziedonis, 2013). RBV regards patents as 
isolating mechanisms against the imitation in prod-
uct markets (Hsu and Ziedonis, 2013). As such, 
patents represent the most important mechanism 
for IP appropriation in the pharmaceutical industry 
and the most effective and the most often used IP 
mechanism for both product and process invention 
(Reitzig and Puranam, 2009; Holgersson, 2013). 
Patents behind successful drugs are responsible for 
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high levels of revenue (Gambardella, 1992; Barret 
et al., 1999; Ravenscraft and Long, 2000).
While patents are a key resource for pharmaceu-
tical firms, their life is limited to a maximum of 20 
years, which means that firms can lose up to 80% 
of its revenue income to generic substitutes when 
these patents expire (Barret et al., 1999; Song and 
Han, 2016). For instance, the expiration in 2011 of 
the patent behind the anti- cholesterol drug Lipitor, 
one of the top- selling drugs of Pfizer, responsible for 
over 16% of the firms’ total revenue, left a sales gap 
of over $10 billion (Kenley, 2011). For the period 
2018– 2024, Deloitte (2019) has forecasted that over 
$251 billion in drug revenues will be at risk because 
patents expiring.
Since patent expiration is a predictable event, it 
is expected that firms will put into place strategies 
and policies that will anticipate patent expiration and 
internally replenish the patent portfolios, avoiding 
disruptions in revenue streams at the time patents are 
due to expire (Gambardella, 1992; Ravenscraft and 
Long, 2000). This process of internal replacement 
is feasible for those firms with innovative capabil-
ity. Innovative capability, manifested through firms’ 
basic research and internal R&D efforts, permits the 
generation of knowledge which is protected by pat-
ents (Elmquist and Le Masson, 2009; Puranam et al., 
2009; Martínez- Román et al., 2011; Cheng and Yang, 
2017). Basic research is essential for the knowledge 
creation process of firms (Griliches, 1990; Tijssen, 
2004), and it is key for internalizing, modifying, and 
applying external knowledge (Cohen and Levinthal, 
1990). Basic research provides firms with a tech-
nological landscape in which they can search for 
new innovations and guides them toward promising 
drugs in the drug discovery process (Fleming and 
Sorenson, 2004). The discovery and development 
process of drugs is a long and complex process that 
requires significant internal R&D efforts such as the 
establishment of R&D labs, the hiring of scientific 
personnel, and large investments in R&D (Cardinal 
and Hatfield, 2000). Nevertheless, this process of 
replenishing the patent pipelines via internal devel-
opment is long and entails significant amounts of 
R&D expenditures and high uncertainty (Frantz, 
2006). It takes an average of 10 years for a new drug 
to complete all the phases from initial discovery to its 
launch into the market with an estimated cost of $2.6 
billion (PhRMA, 2015) and the probability that the 
drug will be eventually approved by the FDA is less 
than 12% (PhRMA, 2015).
Firms failing to fully replenish their patent port-
folio can expect gaps in their product portfolio, 
a decrease in their revenue streams, and an excess 
capacity, as specialized human and physical capital 
becomes redundant and unproductive (Danzon et 
al., 2007). In the long term, the immediate decrease 
in their revenue streams will also disrupt the future 
capacity of the firm to afford R&D activities, as 
current sales are the main source of firms’ finance 
for R&D (Vernon, 2005). Thus, firms that are expe-
riencing poor R&D results or with weak innovation 
capabilities might anticipate a further deterioration 
of their innovation performance resulting from patent 
expiration (Ornaghi, 2009).
RBV theory sustains that due to the difficulty 
and cost of in- house new patent development, firms 
often view acquisitions as a mechanism to achieve 
competitive advantage (Wernerfelt, 1984). Moreover, 
since firms’ resources are not readily exchanged on 
the market, acquisitions represent the main means for 
bringing bundles of resources into firms (Wernerfelt, 
1984; Yu et al., 2016). In the context of patent expi-
ration, pharmaceutical firms might engage in hori-
zontal acquisitions, which provide access to specific 
technologies that are owned by the target firm 
(Birkinshaw et al., 2000; Ranft and Lord, 2002; 
Graebner, 2004).1 Acquiring firms can exploit the 
capabilities and the know- how of the target firm that 
will allow them to develop further innovations (Ranft 
and Lord, 2002; Lamont et al., 2019).
Hence, since the process of drug discovery and 
patent generation takes a considerable risk, time and 
investment, and success rates are low (DiMasi, 2001; 
Rothaermel and Hess, 2007; LaMattina, 2011), phar-
maceutical firms unable to internally replace their 
expiring patents are expected to have a higher prob-
ability of engaging in acquisitions. Thus, the follow-
ing hypotheses are derived:
Hypothesis 1a: Patent expiration positively influences 
firms’ decisions to engage in horizontal acquisitions.
Hypothesis 1b: Newly generated patents negatively 
moderate the effect of patent expiration on firms’ de-
cisions to engage in horizontal acquisitions.
Hypothesis 1c: Internal R&D efforts negatively 
moderates the effect of patent expiration on firms’ 
decisions to engage in horizontal acquisitions.
Hypothesis 1d: Basic research negatively moderates 
the effect of patent expiration on firms’ decisions to 
engage in horizontal acquisitions.
2.2.  The impact of patent expiration on 
pharmaceutical firms’ target selection
RBV understands acquisitions as opportunities to 
redeploy strategic resources both to and from targets 
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(Capron, 1999). Acquisitions grant the acquiring 
firm the possibility of applying control over the 
assets, human capital and technologies of the 
acquired firm, such as the patents portfolio, and use 
them in a way that satisfy its current needs (Folta, 
1998; Schilling and Steensma, 2002), providing a 
greater potential for development of core techno-
logical capabilities and exploitation of competitive 
advantages (Leonard- Barton, 1995). In the context 
of patent expiration, pharmaceutical firms looking 
to replenish their patent portfolio and maintain their 
revenue streams might engage in acquisitions to 
gain access to technological assets held by the target 
firm (Birkinshaw et al., 2000; Ranft and Lord, 2002; 
Ahuja and Katila, 2001; Graebner, 2004). They will 
look for target firms for which they can immediately 
exploit their resources and capabilities, in particular, 
for targets with rich patent portfolios to prevent the 
above- mentioned disruptions (Ranft and Lord, 2002; 
Cloodt et al., 2006; Lamont et al., 2019). Thus, the 
following hypothesis is derived: 
Hypothesis 2a: In the presence of patent expiration, 
acquiring firms will be more likely to choose a target 
with a high patenting output.
In order to capitalize on the targets’ resources, previ-
ous studies examining post- M&A performance have 
indicated the importance of target selection. These 
studies emphasize the strategic fit between target and 
acquirer as the main driver of the success of acquisi-
tions, and in particular, the combination of distinct 
yet related resources and capabilities of both enti-
ties (Shelton, 1988; Larsson and Finkelstein, 1999; 
Kim and Finkelstein, 2009; Makri et al., 2010; Sears, 
2017).
In technological acquisitions, the relatedness of 
acquirer’s and target’s technological knowledge has 
been identified as a determinant of acquisitions’ inno-
vation outcomes (Ahuja and Katila, 2001; Cassiman 
et al., 2005; Cloodt et al., 2006; Makri et al., 2010). 
On the one hand, similarities between acquirers’ 
and targets’ knowledge bases promote economies of 
scale and scope of R&D (Gerpott, 1995; Hagedoorn 
and Duysters, 2002), smooth the integration of the 
knowledge bases (Kogut and Zander, 1992; Grant, 
1996), and facilitate the evaluation and utilization 
of the acquired knowledge (Cohen and Levinthal, 
1990; Cloodt et al., 2006). Because of the similarities 
between the knowledge bases, a related target might 
fail to contribute to the expansion of the knowledge 
base and innovation of the acquiring firm (Ahuja and 
Katila, 2001; Cloodt et al., 2006). On the other hand, 
differences between the knowledge bases of acquirers 
and targets may enrich the acquiring firm’s knowl-
edge base and facilitate learning (Hitt et al., 1994; 
Cloodt et al., 2006). Unrelatedness of the knowledge 
bases might spur innovation through the combina-
tion of acquirers’ and targets’ knowledge (Cohen and 
Levinthal, 1990) and through an improved capacity 
to absorb knowledge from the firms’ external envi-
ronment (Ahuja and Katila, 2001).
Complementarity in acquisitions might be 
attractive to pharmaceutical firms as a way to enter 
new pharmacological areas and commercialize new 
products (Yu et al., 2016). For example, many stud-
ies have reported the acquisition of biotech firms 
as a way to access their specialized knowledge 
and their molecules and compounds (Schweizer, 
2005; Malerba and Orsenigo, 2015). Nevertheless, 
the success of these acquisitions is partly based on 
the capacity of pharmaceutical firms to absorb and 
exploit the newly acquired knowledge and innova-
tion products (Ahuja and Katila, 2001; Yu et al., 
2016).
This paper argues that acquirers facing patent 
expiration will prefer similar over complementary 
targets to ensure sustained performance. While 
complementarity can offer the above- mentioned 
benefits, targets that are too dissimilar would make 
it difficult for the acquirer to assimilate and com-
mercially exploit the new knowledge (Lane and 
Lubatkin, 1998; Cohen and Levinthal, 1990), as the 
process of integration of knowledge is resource- and 
time- consuming (Haspeslagh and Jemison, 1991; 
Graebner et al., 2017). Acquirers facing patent expi-
ration will focus on avoiding gaps in their pipelines 
and drop in their revenue streams, aiming for business 
continuity (Fernald et al., 2017). By selecting simi-
lar targets, acquirers minimize the post- integration 
problems and possible disruptions derived from the 
difficulties in assimilation and commercial exploita-
tion of distant knowledge, ensuring an immediate use 
of acquired resources. Hence, pharmaceutical firms 
looking for replacing their expiring patents will most 
likely target firms with a large patent portfolio and 
similar characteristics. Thus, the following hypoth-
esis is derived:
Hypothesis 2b: In the presence of patent expira-
tion, acquiring firms will be more likely to choose 
a target with a greater similarity in their patent 
portfolio.
3.  Data and methodology
3.1.  Dataset
I constructed a dataset of 93 horizontal acquisitions 
among publicly listed US pharmaceutical firms (as 
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defined by firms in SIC 28) during the 1985– 2010 
period. It includes information on all publicly listed 
US firms involved in acquisitions over the period 
1985– 2010 where at least one of the acquisition par-
ties is actively involved in innovation activities in 
the sense that it has applied for at least one patent 
at the United States Patent and Trademark Office 
(USPTO) since its foundation. Information about 
the acquisition deals was extracted from the data-
base Thomson One Banker provided by Thomson 
Reuters. I consider only those deals that were com-
pleted and which involved majority ownership, and 
also excluded minority deals, acquisition of assets 
(same target and acquiring firm), deals with more 
than two parties and uncompleted deals. The acqui-
sition data were linked to firms’ financial records 
that were retrieved from Compustat. Information on 
the patent activity of firms is taken from the NBER 
patent database and the Coleman Fung Institute for 
Engineering Leadership database (Li et al., 2014). 
The information on firms’ basic research activities 
is extracted from the Medline- Science Citation Index 
(Web of Science) from Thomson Reuters that con-
tains information on publications.
3.2.  Variables
A description of the variables is displayed in 
Table 1. I conceptualized the decision of pharmaceu-
tical firms to undertake an acquisition with a dummy 
variable that takes the value one when the pharma 
firm acquires another pharmaceutical firm and zero 
otherwise; that is, the dependent variable is equal to 
one only on the year of the acquisition.
The main independent variable, patent expira-
tion, is measured as the stock of expiring patents in 
any given year. Following previous studies, I proxy 
innovative capability with R&D efforts and basic 
research (see e.g., Baden- Fuller and Pitt, 1996). 
R&D efforts are measured as the yearly R&D expen-
ditures of the firm. Previous studies have pointed out 
the importance of R&D expenditures in the genera-
tion of innovation and patents, finding a strong rela-
tionship between R&D expenditures and patenting 
output (e.g., Pakes and Griliches, 1980; Hausman et 
al., 1984; Jaffe, 1986). Basic research is measured 
with the number of firms’ scientific publications in 
Journal Citation Reports (JCR) journals. The number 
of scientific publications has been shown to reflect the 
underlying research activity of pharmaceutical firms 
(Gambardella, 1992; Fabrizio, 2009), particularly of 
firms’ investments in basic science (Gambardella, 
1992; Cockburn and Henderson, 1998). Firms’ pub-
lication stock in year t is calculated as the number of 
publications in year t plus the publication stock in 
year t- 1, which is multiplied by 0.85 to reflect a 15% 
depreciation rate (Hall, 1990).
Since patent expiration may not be the only rea-
son for engaging in acquisition activities, I control 
for several firm characteristics that indicate alter-
native explanations for firms’ acquisition decisions. 
Thus, in line with previous studies, I include firms’ 
size to capture the possibility of firms’ merging to 
achieve economies of scale, sales, to contemplate 
Table 1. Definition of variables
Variables Definition
Dependent variable
M&A Equals one if the pharma firm acquires another pharmaceutical firm in year t 
and zero otherwise
Independent variables
Assets Log of assets in year t (in millions)
Sale Sales in year t (in millions), as a ratio of assets
Cash Cash in year t (in millions), as a ratio of assets
Debt Debt in year t (in millions), as a ratio of assets
New patents Number of granted patents applications over the publication stock in year t
Expiring patents Stock of expiring patents in year t (in thousands)
R&D R&D expenditures of the firm in year t (in millions of dollars), as a ratio of 
assets
Publications Number of publications in year t over the publication stock in year t (with a 
15% depreciation rate)
Target assets Log of assets in year t of target firm (in millions)
Target sales Sales in year t of target firm (in millions), as a ratio of assets
Target patents Number of target’s granted patents applications in year t
Overlap Number of patent classes in which both target and acquirer firms patent over 
the total number of patent classes the acquirer firm is active in year t
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firms’ excessive capacity as a driver of the acqui-
sition decision, and cash and firms’ debt to control 
for firms’ ability to finance the acquisition (Higgins 
and Rodriguez, 2006; Danzon et al., 2007). Finally, 
I proxy the ability to generate new innovation output 
with the number of granted patents applications per 
year2 (Griliches, 1990).
For the second part of the analysis, potential 
targets’ characteristics are also included. Similar 
to the acquirer firms’ measures, I include target 
firms’ size, target firms’ sales, and targets’ number 
of granted patents applications in year t. Finally, to 
measure the similarity between targets’ and acquir-
ers’ knowledge bases, I calculate the overlap of the 
patent portfolios as the number of patent classes in 
which both target and acquirer firms patent over the 
total number of patent classes the acquirer firm is 
active in year t.
3.3.  Model and estimation technique
To analyze the impact of patent expiration rate on 
pharmaceutical firms’ decision to acquire a poten-
tial target, I follow an approach similar to Kaul and 
Wu (2016) and include all possible combinations 
of acquirer- target. To mitigate concerns of sample 
selection, I include all US publicly listed pharma-
ceutical firms (SIC 283) that are active in the period 
1985– 2010, 427 firms, as potential acquirers. This 
yields 169,613 target- acquirer- year combinations, 
including the 93 actual acquisitions.3
This empirical set- up implies that the dependent 
variable will be one in very few cases (93 cases) so 
that the sample is dominated by zeroes in the depen-
dent variable. Previous studies have shown that in 
these situations, traditional logit models tend to 
underestimate the probability of rare events, which 
produces biased estimates (King and Zeng, 2001; 
Allison, 2012). To avoid this problem, I make use 
of penalized maximum likelihood estimation (Firth, 
1993; Heinze and Schemper, 2002).
4.  Empirical results
Tables 24, 3, and 4 show the descriptive statistics, a 
comparison of means and medians, and the correla-
tions of the variables of interest, respectively.
Table 55 presents the penalized maximum likeli-
hood logit estimation results. The first column shows 
the basic specification that includes exclusively the 
effects of firms’ characteristics on the probability of 
pharmaceutical firms to engage in acquisition activi-
ties. I find that larger firms are more likely to engage 
in acquisitions. A decrease in sales increases the 
likelihood of firms’ acquisition decisions, while cash 
and debt have a positive effect. Moreover, firms with 
greater patenting output are less likely to engage in 
acquisitions. Column 2 displays the results when the 
patent expiration is included. I find a significant pos-
itive impact of the patent expiration on the likelihood 
to engage in acquisitions. Thus, this result supports 
hypothesis 1a.
Column 3 shows that the interaction term between 
expiring patents and new patents is negative, indicat-
ing that the positive effect of patent expiration on the 
decision to engage in acquisitions is diminished by 
the amount new patents the acquiring firm is inter-
nally producing, hence supporting hypothesis 1b.
Columns 4 to 7 build on specification 2 and 
include the moderating effect of firms’ innovative 
capability on the decision to engage in acquisi-
tions. The coefficients for R&D and the interaction 
of R&D with patent expirations are not significant, 
not supporting hypothesis 1c. In columns 6 and 7, I 
find that firms with a larger basic research base are 
Table 2. Descriptive statistics
Variables Obs. Mean Std. Dev. Min. Max.
Assets 169,613 1,467.408 6,295.903 0 212,949.000
Sale 169,613 1,000.372 4,005.341 −21.796 67,791.000
Cash 169,613 136.317 623.617 −0.476 19,355.000
Debt 169,613 201.350 896.460 0 43,193.000
New patents 169,613 29.550 205.191 0 5,088.000
Expiring patents 169,613 0.433 5.080 0 119.273
R&D 169,613 144.225 570.501 0 12,183.000
Publications 169,613 45.512 205.003 0 4,282.603
Target assets 169,613 1,375.656 5,401.308 0.113 44,031.720
Target sales 169,613 844.853 3,140.436 0 22,833.910
Target patents 169,613 26.957 87.801 0 561.000
Overlap 169,613 0.221 0.341 0 1
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significantly less likely to acquire other firms when 
faced with higher patent expiration rates, thus sup-
porting hypothesis 1d.
Table 66 presents the results of the second part 
of the analysis. Columns (1) and (2) are the same as 
the first two columns of Table 5. Column 3 shows 
that targets’ assets and patenting output significantly 
affect the acquisition decision. First, I find that tar-
gets’ size negatively affects the probability of acqui-
sition, suggesting that acquiring firms might prefer 
smaller targets. Second, firms with a larger patenting 
output are more likely to be acquired, suggesting that 
target firms with a pipeline full of new patents are 
more attractive for acquisition. In column 4, how-
ever, when interacting patent expiration with targets’ 
patents, I do not find a significant effect, not confirm-
ing hypothesis 2a, meaning that expiration does not 
affect the preference for targets with a larger patent 
portfolio.
Columns 5 and 6 show the preference of acquiring 
firms for similar/dissimilar targets. Acquiring firms 
show a preference for firms with dissimilar knowl-
edge bases, reflected in the negative coefficient of the 
overlap in the patent portfolios. However, as shown 
by the positive sign of the interaction term between 
overlap and patent expiration, they do prefer less dis-
tant targets when facing patent expiration, confirm-
ing hypothesis 2b.
Figures 1- 3 display the marginal effects of patent 
expiration. The marginal effects are increasing with 
the number of expiring patents, meaning that firms 
with a larger amount of expiring patents have a higher 
probability of acquiring another pharmaceutical firm. 
Moreover, the marginal effects for internal basic 
research and new patents are decreasing, meaning 
that firms with a higher internal capacity to generate 
innovations and patents have a lower probability of 
engaging in acquisitions given patent expiration.
5.  Discussion
The empirical results demonstrate that the loss of 
competitive advantage derived from the expiration of 
patents, a key technological asset of pharmaceutical 
firms, is a mechanism that drives pharmaceutical firms’ 
acquisition decisions. As highlighted by previous lit-
erature, greater levels of patent expiration increase 
the exposure of pharmaceutical firms to disruptions 
in their product pipelines and revenues streams and 
urge them to come up with new patents (Gambardella, 
1992; Barret et al., 1999; Ravenscraft and Long, 2000; 
Schweizer, 2005; Comanor and Scherer, 2013). This is 
in line with previous financial economics and indus-
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of patent expiration on acquisition likelihood (Higgins 
and Rodriguez, 2006; Danzon et al., 2007). The results 
suggest that the necessity to replace expiring patents 
as quickly as possible to minimize the disruptions 
increases the likelihood of undertaking an acquisi-
tion strategy. This is in line with previous literature 
that highlights the preference of firms for acquisitions 
when the desired technologies and resources at stake 
are characterized by high levels of uncertainty and tac-
itness (Folta, 1998; Hagedoorn and Duysters, 2002; 
Schilling and Steensma, 2002).
The paper also considers different moderators 
for the effect of patent expiration on firms’ acqui-
sition decisions. First, the results show that firms’ 
internal basic research efforts negatively moderate 
the impact of patent expiration on the likelihood 
to engage in acquisitions. Higher levels of basic 
research correspond to higher levels of activity 
particularly in the early stages of the drug discov-
ery process (Gambardella, 1992; Hicks, 1995). The 
results suggest that firms that have a strong basic 
research base possess the raw material necessary 
to come up in- house with new drugs and pat-
ents. Thus, even if the number of expiring patents 
increases, firms with high levels of basic research 
always have some molecules and compounds in 
their pipeline that can be further developed into 
drugs and be exploited in the form of patents, 
reducing their necessity of obtaining these new 
technologies and knowledge from outside the firm. 
This is consistent with the view that basic research 
facilitates the research process of firms, pointing 
them toward new and promising fields (Fleming 
and Sorenson, 2004), and increasing their absorp-
tive capacity (Cohen and Levinthal, 1990). This 
means that firms with a higher basic research base, 
and thus a higher potential to internally generate 
new innovations and patents, have a lower prefer-
ence for acquisitions when patent expiration rates 
increase.
However, the results do not find support for a 
moderation effect of the R&D efforts (measured as 
R&D expenditures). This is surprising given that 
R&D expenditures have been traditionally linked 
with a higher capacity to develop innovations inter-
nally (Hausman et al., 1984; DiMasi et al. 2003). 
This apparent contradiction might be explained by 
the fact that R&D expenditures are the input for inno-
vation, so that higher levels of R&D may not nec-
essarily indicate progress in developing compounds 
(DiMasi et al., 2003). In particular, recent research 
indicates that attrition rates, development times, and 
R&D expenditures have all increased since the mid- 
1990s (Cockburn, 2006; Pammolli et al., 2011). This 
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input– output indicates that innovation has become 
more challenging and thus, R&D expenditures no 
longer necessarily translate into patents (Pammolli et 
al., 2011; Scannell et al., 2012).
The results for target selection analysis suggest 
that firms engage in acquisitions to gain access to 
technological assets held by the target firm, which 
is in line with the literature on technological acquisi-
tions (e.g., Birkinshaw et al., 2000; Ranft and Lord, 
2002; Ahuja and Katila, 2001; Graebner, 2004). First, 
the results show that independent of the patent expi-
ration of acquiring firms, pharmaceutical firms have 
a preference for targets with rich patent portfolios, 
which coincides with the findings of mainstream 
studies on technological acquisitions (Cloodt et al., 
2006). Surprisingly, the results did not show any 
impact of patent expiration on the preference for 
targets with greater patent portfolios. This might be 
because, in the pharmaceutical industry, patents are 
the main output of innovation, with innovation being 
the primary activity in the industry, so that patents 
could be seen as a pre- requisite for acquiring firms, 
regardless of the motives behind the acquisition.
Finally, the results show that acquiring firms 
prefer for targets with a more distant knowledge 
base, emphasizing the importance of accessing 
Table 6. Logit for target selection
Variables
(1) (2) (3) (4) (5) (6)
Baseline 










Assetst 0.235*** 0.229*** 0.231*** 0.231*** 0.223*** 0.224***
(0.009) (0.009) (0.009) (0.009) (0.009) (0.009)
Salet −0.538*** −0.562*** −0.570*** −0.570*** −0.610*** −0.615***
(0.059) (0.059) (0.060) (0.060) (0.060) (0.060)
Casht 0.000*** 0.000*** 0.000*** 0.000*** 0.000*** 0.000***
(0.000) (0.000) (0.000) (0.000) (0.000) (0.000)
Debtt 0.092*** 0.090*** 0.092*** 0.092*** 0.098*** 0.099***
(0.019) (0.020) (0.020) (0.020) (0.020) (0.020)
New patentst −2.253*** −2.277*** −2.282*** −2.282*** −2.206*** −2.207***
(0.135) (0.137) (0.136) (0.136) (0.136) (0.136)
Expiring patentst 0.017*** 0.017*** 0.017*** 0.016*** 0.015***
(0.002) (0.002) (0.002) (0.002) (0.002)
Target assetst −0.017* −0.017* 0.015 0.014
(0.010) (0.010) (0.011) (0.011)
Target salest 0.004 0.004 −0.001 −0.001
(0.023) (0.023) (0.024) (0.024)
Target patentst 0.280*** 0.280*** 0.282*** 0.282***
(0.074) (0.075) (0.073) (0.073)










Constant −4.893*** −4.872*** −4.876*** −4.876*** −4.883*** −4.783***
(0.050) (0.050) (0.066) (0.066) (0.066) (0.066)
Number of 
observations
169,613 169,613 169,613 169,613 169,613 169,613
Log likelihood −11,256 −11,214 −11,195 −11,190 −11,155 −11,159
Standard errors in parentheses.
***P < 0.01, **P < 0.05, *P < 0.0.1.
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new knowledge, technologies, and possibilities for 
recombination of knowledge for potential acquiring 
firms. This is in line with the literature supporting 
complementarities as a key for successful acquisi-
tions (Shelton, 1988; Larsson and Finkelstein, 1999; 
Capron and Mitchell, 2009; Kim and Finkelstein, 
2009; Makri et al., 2010; Kaul and Wu, 2016). 
However, I also find that firms facing patent expira-
tion prefer less distant targets as a way to secure their 
revenue streams and substitute existing knowledge 
and patents, rather than to explore new knowledge 
or get access to knowledge that eventually can lead 
to new technologies. By selecting similar targets, 
acquirers minimize the post- integration problems 
and possible disruptions derived from the difficul-
ties in assimilation and commercial exploitation of 
distant knowledge, ensuring an immediate use of 
acquired resources. In this sense, the findings on the 
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interaction of patent expiration and the overlap of 
technological portfolios support the literature indicat-
ing that acquirers benefit from similar targets (Baum 
et al., 2000; Schildt and Laamanen, 2006; Berchicci 
et al., 2012; Chakrabarti and Mitchell, 2013).
6.  Conclusion
Framed in the RBV literature, this paper contributes 
to previous research on acquisition motives and tar-
get selection by studying the impact of patent expi-
ration on pharmaceutical firms’ acquisition timing 
and target selection. The results show that patent 
expiration is a triggering factor of firms’ acquisition 
decision, which is explained by the short- term neces-
sity of firms to fill the pipeline gaps left by expiring 
patents and to maintain revenue streams. This effect 
is moderated by firms’ innovative capability. In par-
ticular, for firms with a stronger basic research base 
and newly generated patents, the effect of patent 
expiration on the acquisition decision is not as pro-
nounced. This is because innovative capability facil-
itates firms’ research process, providing them with 
a higher capability to internally generate new inno-
vations, thus reducing the external dependency. The 
results also show that pharmaceutical firms facing 
patent expirations prefer targets with a strong pat-
ent portfolio and with a certain level of similarity in 
their knowledge bases. Pharmaceutical firms sacri-
fice potential gains in innovation from distant targets 
to ensure a quick and easy integration that facilitate 
the exploitation and commercialization of the target’s 
knowledge, avoiding disruptions in the pipelines and 
revenue flows.
6.1.  Managerial and policy implications
This study suggests that managers should pay atten-
tion to and plan for long- term innovation strategies. 
Patent expiration is a highly disruptive event in the 
pharmaceutical industry that can erode firms’ com-
petitive advantage. The results show that clever pat-
ent portfolio management can avoid the so- called 
‘patent cliff’ and the consequent disruption in reve-
nues (Kenley, 2011; LaMattina, 2011). In particular, 
the strategic timing of patent applications as well as 
strong internal research capabilities can avoid deple-
tion of firms’ patent portfolio and the associated 
disturbances in the pharmaceutical pipelines. This 
is particularly important in light of the innovation 
output declines reported by the post- M&A litera-
ture, which suggests that because of their complex-
ity M&As do not always bring the intended positive 
outcomes. Thus, managers should carefully manage 
their patent portfolios to avoid having to undertake 
M&As as a response to patent expiration.
The results provide policymakers and practi-
tioners with a set of indicators that helps to explain 
the acquisition behavior and target choice of pharma-
ceutical firms. For its vast majority, the existing indi-
cators are based on firms’ financial information (e.g., 
market capitalization, ratio cash to sales, Tobin’s q), 
or trends (e.g., industry trends or acquisition waves). 
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As compared to these, patent expiration does not rely 
on the financial situation of the firm but rather on the 
innovation portfolio, which from the empirical point 
of view is less problematic in terms of causality and 
endogeneity.7 Thus, policymakers and practitioners 
should closely monitor innovation indicators as a 
way to anticipate the acquisition activity of pharma-
ceutical firms.
6.2.  Limitations and further research
As any, this study is not free of limitations. First, these 
results refer to the pharmaceutical industry, and thus, 
cannot be translated into low innovative industries or 
industries in which trade secrecy is the major strat-
egy to protect innovation breakthroughs. Second, this 
paper focuses on acquisitions of new patents through 
acquisitions, ignoring other mechanisms such as pat-
ents’ rights transfers8 or patent licensing. Thus, it 
may be interesting to complement the current study 
with patent transfer and patent licensing data.
Future research could also investigate how much 
does patent expirations weight in the decision to 
engage in acquisitions as compared to other factors 
such as financial performance (Meyer- Doyle et al., 
2019). Future research could also complement the 
current patent- level analysis with a drug- level study, 
by, for example, matching individual patents to dif-
ferent drugs. Another topic of relevance would be to 
investigate the role that marketing might play in miti-
gating the losses derived from patent expiration (Jain 
and Conley, 2014).
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Notes
 1 While firms can also resort to internal development, al-
liances, R&D outsourcing, licensing or joint ventures 
to develop new technologies (Arora and Gambardella, 
1990; Cockburn and Henderson, 1998; Xu and 
Cavusgil, 2019), in high- tech industries acquisitions 
might be preferred (Arora and Gambardella, 1990; 
Haspeslagh and Jemison, 1991; Hitt et al., 1994). In 
particular, when firms are seeking for technological re-
sources that provide with a sustainable competitive ad-
vantage and above- normal economic rents, acquisitions 
offer greater potential for core technological capability 
development (Leonard- Barton, 1995; Hagedoorn and 
Duysters, 2002). Acquisitions and internalization of key 
technological resources facilitate the coordination of 
asset- specific activities (Schilling and Steensma, 2002) 
and provide a better governance mechanism (through 
the share routines, knowledge and language developed 
within firms) for resources that are unique, tacit, and 
difficult to imitate (Kogut and Zander, 1992; Grant, 
1996).
 2 Granted patents are preferred to other patent indica-
tors such as patent applications because the former is 
an indicator of successful invention (Ahuja and Katila, 
2001).
 3 Note that while all possible combinations of target- 
acquirer- year are considered, only those years’ combi-
nations for which data on the target and acquirer are 
available are included.
 4 Note that for those variables for which I have taken the 
log (e.g., size) or taken the variable as a ratio, the table 
of descriptive statistics refers to the variables before 
being transformed.
 5 In the appendix, Tables A1 and A2 show the robustness 
checks for this part of the analysis. Table A1 displays the 
results with the lagged variables of the financial vari-
ables. Table A2 displays the results with the citations- 
weighted expiring patents, calculated as in Trajtenberg 
(1990), as main independent variable. The results are in 
line with the main analyses.
 6 In the appendix, Table A3 shows the robustness checks 
for this second part of the analysis. Table A3 displays 
the results with the citations- weighted expiring pat-
ents, calculated as in Trajtenberg (1990), as main inde-
pendent variable. The results are in line with the main 
analysis.
 7 This is because patent expiration is exogenous to the 
firm since patents’ life duration is externally fixed by 
the USPTO; exogeneity, however, cannot be ensured 
with financial indicators since changes in firms’ finan-
cial statements may be a response to firms’ acquisition 
decision, through for example a managerial change in 
strategy or as a consequence of markets’ rumors about 
the acquisition.
 8 The USPTO Patent Assignment Dataset collects infor-
mation on patents’ transfers (either individually or in 
a bundle). These datasets, however, suffer from several 
limitations that complicate the analysis: (1) names of 
buyers and sellers are not standardized on the dataset, 
which makes tracking a very difficult task; (2) the data-
base does not allow distinguishing between patents ac-
quired to be exploited or patents acquired to be licensed 
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out (Serrano, 2010). Moreover, in his study of patent 
transfer, Serrano (2010) indicates that for the drugs and 
medical industry, patent transfer represents only about 
16%. He also recognizes that this dataset, however, 
does not distinguish between the acquisition of a bun-
dle of patents from the acquisition of a firm, meaning 
that there are large amounts of overlapping between the 
USPTO Patent Assignment Dataset and the acquisition 
dataset.
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